Sangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $10.36 million.

GUIDANCE:

Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of $33.24 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.